SPY322.33-0.31 -0.10%
DIA267.02-0.56 -0.21%
IXIC10,631.57-1.41 -0.01%

Goldman Sachs Downgrades Jazz Pharmaceuticals to Sell, Announces $128 Price Target

Goldman Sachs downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Neutral to Sell and announces $128 price target.

· 09/14/2020 07:43
Goldman Sachs downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Neutral to Sell and announces $128 price target.